[14] Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2004, 22(11):2184-2191.
[15] Herbst RS, Johnson DH, Mininberg E, et al.Phase Ⅰ/Ⅱ trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer[J]. J Clin Oncol, 2005,23(11):2544-2555.
[16] Paz-Ares L, Douillard J, Koralewski P, et al. Randomized phase Ⅲ trial of gemcitabine/cisplatin (GC) and protein kinase C a (PKCa) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC)[J]. Proc Am Soc Clin Oncol, 2005,23:165,7053.
[17] Adjei AA, Erlichman C, Davis JN. A Phase Ⅰ trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity[J]. Cancer Res, 2000,60(7):1871-1877.
[18] Gleave ME. Monia antisense therapy for cancer[J]. BP.Nat Rev Cancer,2005,5(6):468-479.
[19] Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selectivecyclo-oxygenase-2 inhibitor, enhances the response to preoperativepaclitaxel and carboplatin in early-stage non-small-cell lung cancer[J]. J Clin Oncol, 2003,21:2645-2650.
[20] Ferrari M. Cancer nanotechnology: opportunities and challenges[J]. Nat Rev Cancer, 2005,5(3):161-171.
转贴于 酷文网-论文下载中心 http://www.coolwen.net
共4页: 上一页 [1] [2] [3] 4 下一页
网摘收藏:
当前位置:
载入中...
-> 在百度中搜索：
-> 在Google中搜索：